Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEPHALEXIN MONOHYDRATE

All products: general benefit

Other products in the same Health Canada class (J01D, J01DB) — coverage varies; not interchangeable

  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit
  • Cefixime (Suprax): general benefit
  • Cefprozil (Ran-Cefprozil): general benefit, Not a benefit
  • Ceftriaxone (Rocephin): general benefit, Not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit

1 more in the class list below

Auro-Cephalexin · DIN 02470578 · 250mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Cephalexin · DIN 02470578 Manufacturer: Auro Pharma Inc.; listing date 2018-10-31 Daily cost (source): $0.3464 Health Canada: Marketed since 2018-07-30 · brand AURO-CEPHALEXIN · ATC J01DB01 CEFALEXIN · form Tablet · route Oral · ingredients CEPHALEXIN (CEPHALEXIN MONOHYDRATE) 250 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Cephalexin: Formulary list price $0.0866/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0866 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95956 · Verify on the e-Formulary ↗ (DIN 02470578)

Source record
DIN 02470578: Auro-Cephalexin Raw flags: sec3=Y Item: 081228034; group id 43; item number 0098; lccId None; manufacturer id AUR Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0866; ministry $0.0866 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470578 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95956
Interchangeable products
Apo-Cephalex · DIN 00768723 · $0.0866 Cephalexin · DIN 02521253 · $0.0866 Jamp Cephalexin · DIN 02494698 · $0.0866 Keflex · DIN 00403628 · not recorded Lupin-Cephalexin · DIN 02471140 · $0.0866 Teva-Cephalexin · DIN 00583413 · $0.0866
Shortage status: resolved shortage (ended 2024-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470578
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS TEVA-CEPHALEXIN may be indicated for the treatment of bacterial infections of the respiratory tract (1,12)(l3,l4), including otitis media (1,2) , genitourinary tract (3), bone and joints (4,5), skin and soft tissue (6,7), when the infection is caused by susceptible organisms. Culture and susceptibility studies should be performed. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEVA- CEPHALEXIN and other antibacterial drugs, TEVA-CEPHALEXIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 2 https://pdf.hres.ca/dpd_pm/00057614.PDF PM date: August 12, 2020 Source product: TEVA-CEPHALEXIN; DIN 00342084; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.